Survival Benefit in Metastatic Melanoma Grows Larger in COMBI-v Update
Source: The ASCO Post, November 2015
Combined BRAF and MEK inhibition was superior to BRAF inhibition alone in unresectable metastatic melanoma, according to the updated survival analysis of the large randomized COMBI-v trial.1 These findings were reported at the 2015 European Cancer Congress recently held in Vienna, Austria.
“Dabrafenib [Tafinlar] plus trametinib [Mekinist] has demonstrated superiority over BRAF inhibitor monotherapy now in two phase III trials, supporting its use as a standard-of-care therapy in patients with BRAF V600–mutant melanoma,” said lead author Caroline Robert, MD, of Institut Gustave Roussy in Paris.
COMBI-v, which enrolled 704 patients with advanced, treatment-naive BRAF-mutant melanoma, evaluated the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib and compared it with the single-agent treatment with the first-approved BRAF inhibitor vemurafenib (Zelboraf).